Literature DB >> 26314080

Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Joost S Vermaat1, Steven T Pals2, Anas Younes3, Martin Dreyling4, Massimo Federico5, Igor Aurer6, John Radford7, Marie José Kersten8.   

Abstract

Mesh：

Year:  2015        PMID： 26314080      PMCID： PMC5004412          DOI： 10.3324/haematol.2015.128371

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

Review 1.  Next-generation genomics: an integrative approach.

Authors:  R David Hawkins; Gary C Hon; Bing Ren
Journal:  Nat Rev Genet       Date:  2010-07       Impact factor: 53.242

Review 2.  Computational methods for discovering structural variation with next-generation sequencing.

Authors:  Paul Medvedev; Monica Stanciu; Michael Brudno
Journal:  Nat Methods       Date:  2009-11       Impact factor: 28.547

Review 3.  Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Authors:  Sarah Barton; Eliza A Hawkes; Andrew Wotherspoon; David Cunningham
Journal:  Oncologist       Date:  2012-10-18

Review 4.  Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.

Authors:  Piers A Blombery; Michael Dickinson; David A Westerman
Journal:  Leuk Lymphoma       Date:  2013-05-09

Review 5.  Implementing personalized cancer genomics in clinical trials.

Authors:  Richard Simon; Sameek Roychowdhury
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 6.  Genome sequencing of lymphoid malignancies.

Authors:  Charles G Mullighan
Journal:  Blood       Date:  2013-09-16       Impact factor: 22.113

Review 7.  Personalized therapies in the cancer "omics" era.

Authors:  Alberto Ocaña; Atanasio Pandiella
Journal:  Mol Cancer       Date:  2010-07-29       Impact factor: 27.401

Review 8.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 9.  Diffuse large B-cell lymphoma.

Authors:  Maurizio Martelli; Andrés J M Ferreri; Claudio Agostinelli; Alice Di Rocco; Michael Pfreundschuh; Stefano A Pileri
Journal:  Crit Rev Oncol Hematol       Date:  2013-01-30       Impact factor: 6.312

Review 10.  Clonal evolution in hematological malignancies and therapeutic implications.

Authors:  D A Landau; S L Carter; G Getz; C J Wu
Journal:  Leukemia       Date:  2013-08-27       Impact factor: 11.528
View more
  12 in total

1.  A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

Authors:  Thomas Yssing Michaelsen; Julia Richter; Rasmus Froberg Brøndum; Wolfram Klapper; Hans Erik Johnsen; Mads Albertsen; Karen Dybkær; Martin Bøgsted
Journal:  Blood Adv       Date:  2018-07-10

2.  At the intersection of systematic and seismic: examining the way forward for pediatric research.

Authors:  Shari L Barkin
Journal:  Pediatr Res       Date:  2017-09-06       Impact factor: 3.756

3.  Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.

Authors:  Jean-Philippe Jais; Thierry Jo Molina; Philippe Ruminy; David Gentien; Cecile Reyes; David W Scott; Lisa M Rimsza; George Wright; Randy D Gascoyne; Louis M Staudt; Corinne Haioun; Herve Tilly; Philippe Gaulard; Gilles A Salles; Fabrice Jardin; Karen Leroy
Journal:  Haematologica       Date:  2017-07-04       Impact factor: 9.941

Review 4.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

5.  Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.

Authors:  Sharvil P Patel; R Andrew Harkins; Michelle J Lee; Christopher R Flowers; Jean L Koff
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24

6.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

7.  Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.

Authors:  Xiangxiang Zhou; Xiaosheng Fang; Yujie Jiang; Lingyun Geng; Xinyu Li; Ying Li; Kang Lu; Peipei Li; Xiao Lv; Xin Wang
Journal:  J Hematol Oncol       Date:  2017-02-02       Impact factor: 17.388

8.  Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

Authors:  K Karube; A Enjuanes; I Dlouhy; P Jares; D Martin-Garcia; F Nadeu; G R Ordóñez; J Rovira; G Clot; C Royo; A Navarro; B Gonzalez-Farre; A Vaghefi; G Castellano; C Rubio-Perez; D Tamborero; J Briones; A Salar; J M Sancho; S Mercadal; E Gonzalez-Barca; L Escoda; H Miyoshi; K Ohshima; K Miyawaki; K Kato; K Akashi; A Mozos; L Colomo; M Alcoceba; A Valera; A Carrió; D Costa; N Lopez-Bigas; R Schmitz; L M Staudt; I Salaverria; A López-Guillermo; E Campo
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

9.  MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Authors:  Joost S Vermaat; Sebastiaan F Somers; Liesbeth C de Wreede; Willem Kraan; Ruben A L de Groen; Anne M R Schrader; Emile D Kerver; Cornelis G Scheepstra; Henriëtte Berenschot; Wendy Deenik; Jurgen Wegman; Rianne Broers; Jan-Paul D de Boer; Marcel Nijland; Tom van Wezel; Hendrik Veelken; Marcel Spaargaren; Arjen H Cleven; Marie José Kersten; Steven T Pals
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

10.  IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.

Authors:  Xiangli Chen; Yuzhu Zang; Dujuan Li; Jianmin Guo; Yacai Wang; Yuqi Lin; Zhenghong Wei
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.